A company that sold an app called Instant Blood Pressure has agreed to settle a Federal Trade Commission complaint that it deceived consumers with claims that its app was as accurate as a traditional cuff. The FTC also charged that the company posted positive reviews of the app and gave it five stars in app store reviews.
Aura Labs, Inc., has agreed to stop making such claims and, in settling an FTC complaint, has also agreed not to post endorsements of its products without disclosing connections the endorser has with the company, the FTC said.
That's not quite how the company is spinning the settlement on its website, however.
"AuraLife never claimed that the Instant Blood Pressure app’s performance characteristics were equivalent to that of a conventional blood pressure cuff," the company said in a prepared statement. "The Commission does not dispute that AuraLife’s current, smartphone-based blood pressure product does, in fact, provide estimates of blood pressure to the performance characteristics published by the company," Aura Labs says.
Aura Labs also puts the best possible light on a judgment of $595,945.27 levied against the company. The penalty was suspended based on the defendants’ inability to pay, but the "full amount will become due, however, if they are later found to have misrepresented their financial condition," the FTC said.
In its statement, Aura Labs says it "would not have agreed to settle this matter had any payment been required."
|Scooped by Pharma Guy|
To my recollection, this is the second time FTC has given a medical app developer a pass on paying a fine. Luminosity, for example, got away with not paying $50 million because it "can't afford it" (read “FTC Supports Scientific Proof of Digital Health App Effectiveness”; http://sco.lt/7RrRkf ).